Why did Pfizer buy a pharmaceutical company, which is considered one of the market leaders in the development of drugs to treat autoimmune diseases and thrombosis? An evil one who thinks bad about it. The expose program “Impfgehisper” took a closer look at the acquisition of “Arena Pharmaceuticals” by the pharmaceutical giant and analyzed which drugs could be the focus here.
Guest commentary via #VaccinationWhispers. Listen to the current episode here or read the written version below:
Pfizer’s solution to vaccine damage: New drugs to resolve thrombosis and treat autoimmune diseases through purchase of Arena Pharma?
Pharmaceutical giant Pfizer apparently wants to further boost its profits with new cardiovascular treatments. The number of heart failure cases and associated deaths continues to increase significantly around the world. Pfizer is now expanding into myocarditis drugs by gaining control of the heart treatment market through new acquisitions.
The company had announced the purchase of Arena Pharmaceuticals for $6.7 billion last year. Arena Pharma is a market leader in the development of medicines to treat autoimmune diseases and thrombosis, which are often caused by vaccine-related injuries.
Arterial thrombosis is the formation of blood clots or “thrombi” in an artery that restrict or block blood flow. This can lead to acute coronary syndrome or stroke as we have seen all over the news. Athletes, military personnel and celebrities who were vaccinated and then suffered cardiac arrest or even “suddenly and unexpectedly died.”
Pfizer Chief Business Innovation Officer Aamir Malik celebrated the news in a statement about the acquisition:
“We believe this transaction is the best next step for both patients and shareholders.”
Of course, Pfizer thinks of patients first. We demonstrated this effectively in #VACCINE FLUSTER Season 4 Episodes 1-4…
Common side effects of Covid gene therapy drugs
The interesting thing is that they are autoimmune diseases A common side effect of the Biontech/Pfizer Covid vaccination. The company intends to make huge profits by treating these myriad diseases that arise in the vascular systems of millions of people around the world.
At the center of Pfizer’s acquisition of Arena Pharma are drugs like temongrel and atrasimod, which are used to treat Swelling used. One side effect of Pfizer’s Covid shot is spike protein syndrome, which causes chronic inflammation.
Temanogrel is a medical treatment Microvascular blockages (damage to blood vessels) such as thrombosis. Surprisingly, Temanogrel also received FDA fast-track approval in 2020, just like the Covid shots, meaning clinical trials were skipped and the drug was brought straight to market. The business model is called “problem – response – solution”: Temenogrel, also known as APD791, is used to treat arterial thrombosis.
Due to the rapid distribution of lipid nanoparticles throughout the vascular system, the spike protein is rapidly delivered throughout the body via the blood. The spike may continue for months and years after vaccination and no one knows exactly how long.
The IgG4 marker is the immune system’s response to persistent irritation by harmful substances such as spike proteins. Spike production in the body’s own cells also causes autoimmune reactions. Both factors – the persistent presence of spikes in the body’s cells and the autoimmune reactions they trigger – are responsible for the fact that cardiovascular disease, thrombosis and other symptoms can occur long after gene therapy.
Harmful effects are now well documented
In March 2023, the National Institutes of Health (NIH), an agency of the US Department of Health and Human Services, published known adverse events following the administration of COVID-19 mRNA vaccines as documented in clinical trials.
The results also include a systematic review of “cardiovascular complications, thrombosis, and thrombocytopenia” published under the National Library of Medicine and the National Center for Biotechnology Information (Adverse events following COVID-19 mRNA vaccines: a systematic review of cardiovascular complications, thrombosis, and thrombocytopenia).
The VAERS system has been inundated with reports of cardiovascular complications occurring after the first or second dose of mRNA injection.
Cardiovascular complications listed include: “pericarditis/myopericarditis, myocarditis, hypotension, hypertension, arrhythmia, cardiogenic shock, stroke, myocardial infarction/STEMI, intracranial hemorrhage, thrombosis (deep vein thrombosis, cerebral vein thrombosis, arterial or venous thrombotic events , portal vein thrombosis), coronary thrombosis, microvascular small bowel thrombosis) and pulmonary embolism.
BioNTech/Pfizer definitely wants to continue vaccinations. Even small children and infants. It is now well documented that BioNTech/Pfizer relied primarily on speed rather than safety standards in the production of their COVID-19 vaccine Comirnaty – with disastrous results.
It is unclear whether BioNTech/Pfizer’s mRNA COVID-19 vaccine had any positive effects or whether it merely caused serious harm in the form of vaccination-related injuries and even deaths. On August 4, 2023 this year, in response to a request (letter in source) from Bundestag member Roger Bekamp, the Federal Health Ministry also admitted that there was no evidence of effectiveness of the BioNTech/Pfizer product. The reply of Edgar Franke, parliamentary state secretary at the federal health ministry, was brief and serious: “No, the federal government does not have such data.”
After acquiring Arena Pharmaceuticals, Pfizer is likely to earn billions of dollars by selling cardiovascular treatments, As their deaths are increasing. Buying this pharmaceutical company will definitely be beneficial for Pfizer.
Important information will protect you and your family from unwanted side effects!
Thanks for listening, see you next time!
Links Season 4, Episode 5 (Accessed September–October 2023)
Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine, Pollack, MD, et al, N Engl J Med, December 31, 2020. zulasangsstudy.
For all his details in the book “Project Lightspeed,” Miller also intentionally left out important points such as the fact that Ugur Sahin and Ozlem Tureci themselves participated in the approval study of the BNT162b2 mRNA COVID-19 vaccine. If you look at the related publication from December 10, 2020, in the New England Journal of Medicine, the co-authorship of the BioNTech couple is not immediately obvious because other names are mentioned initially. Only when you click on “et al” (“et ali” = and others) do the names Ugur Sahin and Ozlem Tureci appear. Delicate details: The study authors had to disclose in a document whether they had any conflicts of interest. Sahin and Tureci denied this in writing. That was a complete lie.
Written conflict of interest author, page 66ff Sahin, page 84ff Tureci
Batch-dependent safety of the BNT162b2 mRNA COVID-19 vaccine, Max Schmeling et al, European Journal of Clinical Investigation, 30 March 2023
In March this year, Max Schmeling, Vibeke Manniche and Peter Rees Hansen published the results of their study on the safety of the BNT162b2 COVID-19 mRNA vaccine in the biomedical journal European Journal of Clinical Investigation. They were able to clearly demonstrate that the risk of serious side effects was very unevenly distributed across different Comirnaty batches. The investigation is based on official data from Danish authorities, which reported 579 suspected cases of fatal side effects and 14,509 cases of serious – that is, potentially life-threatening – side effects from BioNTech/Pfizer’s mRNA vaccines.
Pfizer Completes Acquisition of Arena Pharmaceuticals, Pfizer Press Release, March 11, 2022
Pfizer finalizes $6.7 billion acquisition of Arena Pharmaceuticals, leading to leading cardiovascular treatments, Michael Walter, Cardiovascular Business, March 14, 2022
Temanogrel, Dr. AM Crasto, Ph.D., Unclassified, New Drug Approvals, 13 June 2016.
The 5-HT 2A receptor is one of 15 different serotonin receptor subtypes.
Modulation of 5-HT 2A receptors on vascular smooth muscle cells and platelets in the cardiovascular system is believed to play an important role in the regulation of cardiac function.
Arena Pharmaceuticals Announces First Participant Randomized in Phase 2 Trial Evaluating Temenogrel in Coronary Microvascular Obstruction (CMVO) June 08, 2021
To evaluate the safety, tolerability, and efficacy of intravenous (IV) temongrel for CMVO in adult participants undergoing percutaneous coronary intervention (PCI) – no FDA approved therapy is currently indicated for the treatment of CMVO – temongrel The treatment was given FDA Fast Track designation. CMVO
Pfizer Announces FDA and EMA Acceptance of Atrasimod Regulatory Submission for Ulcerative Colitis, Pfizer Press Release, December 21, 2022
Adverse events following COVID‐19 mRNA vaccines: a systematic review of cardiovascular complications, thrombosis and thrombocytopenia, Yasmin F, Najeeb H, et al, Immune Inflamm Dis. 2023 march
Class switching toward spike protein-specific IgG4 antibodies after SARS-CoV-2 mRNA vaccination depends on prior infection history Kiesel, P., Sik, P., Miklos, J. et al., Scientific Reports, August 2023
Cytokinopathy with Aberrant Cytotoxic Lymphocytes and Profibrotic Myeloid Response in SARS-CoV-2 mRNA Vaccine-Associated Myocarditis, Anees Barmada et al., Science Immunol, May 2023
Pfizer didn’t know if Covid vaccine stopped transmission before rollout, news.com.au, October 2022
Janine Small, Pfizer hearing in the EU Parliament. Virus transmission has never been tested.
BioNTech, Martina Binnig and Dr. Self-Demonstration. Günter Frank, August 16, 2023
(Tags to translate)Autoimmune disease(T)Heart disease(T)Side effects(T)Pfizer(T)Thrombose